# Vanta Holdings Closes Final $210K Tranche of Private Placement, Total Reaches $334,579.42

> Vanta Holdings closed its second and final private placement tranche, raising $210,000 and bringing total proceeds to $334,579.42.

- Published: 2026-10-17T01:54:51+00:00
- Section: Funding
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-17/vanta-holdings-second-tranche-private-placement
- Source: [TradingView](https://www.tradingview.com/news/tradingview:23efce4d68484:0-vanta-holdings-inc-vnta-closes-second-tranche-raises-210k/)

## Key takeaways

- Vanta Holdings issued 210,000 units at $1.00 per unit in the second and final tranche of its non-brokered private placement.
- Total proceeds from the placement reached $334,579.42, with warrants at $1.25 expiring October 15, 2028.
- Vanta Holdings reported C$18,000 revenue and a C$648,000 net loss in Q2 2026, according to AInvest.

[Vanta Holdings](https://akta.pro/company-profiles/00qtri9/vanta-holdings) Inc. closed the second and final tranche of its non-brokered private placement, issuing 210,000 units at $1.00 per unit for $210,000 and bringing total proceeds to $334,579.42, [TradingView](https://www.tradingview.com/news/tradingview:23efce4d68484:0-vanta-holdings-inc-vnta-closes-second-tranche-raises-210k/) reported. The company said the proceeds will be used to pay obligations and support corporate awareness.

## Vanta Holdings' Second Tranche Details

The second tranche consisted of 210,000 units priced at $1.00 per unit, raising $210,000. Each unit includes a warrant exercisable at $1.25, with an expiration date of October 15, 2028. The total placement proceeds of $334,579.42 combine the first and second tranches.

Vanta Holdings said the funds will go toward paying obligations and corporate awareness. The hold period for the securities runs to February 17, 2027. The company is advancing a planned peptide and nutraceutical strategy, according to the report.

## Vanta Holdings' Funding Records

According to akta.pro [company records](https://akta.pro/company-data), Vanta Holdings closed the first tranche of the private placement at CAD $385,000 in May 2026, issuing 385,000 units at $1.00 per unit with warrants exercisable at $1.25 until May 5, 2028. The same records show two funding rounds on file, including post-IPO equity of $90,252 and $735,037, both dated May 2026. Total funding stands at $800,000, with a valuation estimate of $10 million to $50 million.

| Funding figure | Amount |
|---|---|
| First tranche (May 2026) | CAD $385,000 |
| Post-IPO equity (May 2026) | $90,252 |
| Post-IPO equity (May 2026) | $735,037 |
| Total funding | $800,000 |

## Vanta Holdings' Earlier 2026 Events

Vanta Holdings reported C$18,000 revenue and a C$648,000 net loss in Q2 2026, and its private placement closed for only C$124,579, AInvest reported in September 2026. The company has not sold any peptide therapies, according to the same report.

In August 2026, Vanta Holdings engaged Toronto-based Independent Trading Group to provide market-making services for its common shares on the Canadian Securities Exchange and other venues, Stock Titan reported. In July 2026, the U.S. FDA Pharmacy Compounding Advisory Committee voted to recommend the inclusion of six peptide substances, including BPC-157, TB-500, and MOTS-c, on the FDA's 503A Bulks List, a decision Vanta Holdings publicly commended, Yahoo reported.

## Vanta Holdings' Warrant Expiration

The warrants issued in the second tranche are exercisable at $1.25 and expire on October 15, 2028. The hold period for the securities extends to February 17, 2027.

## Companies in this story

- [Vanta Holdings company profile](https://akta.pro/company-profiles/00qtri9/vanta-holdings) · website: https://vantablackwater.com

---
News for Agent · https://newsforagent.com/llms.txt